S73 Impact of Early Biologic Therapy Initiation Following Crohn’s Disease Hospitalization: A Multicenter Retrospective Analysis

Abstract

ulcerative colitis. The purpose of this study it to determine the impact of ustekinumab trough levels and clinical outcomes in patients with inflammatory bowel disease. Methods: This is an investigational review board (IRB) approved retrospective cohort study of adult IBD patients seen at the ULP Gastroenterology Office between January 1, 2016 and December 31, 2022. Patients 18 years of age and older who have a diagnosis of either Crohn's disease or ulcerative colitis and have been initially infused with ustekinumab will be included in the study. Patients on any maintenance dose of ustekinumab at a dosing frequency longer than 8 weeks or currently using another biologic will be excluded. Patients with both types of IBD will be divided into 3 treatment arms: ustekinumab trough levels ,2.0, trough levels 2.0 to 4.5, and trough levels . 4.5. The primary endpoint will be Crohn's Disease Activity Index (CDAI) in Crohn's disease and Simple Clinical Colitis Activity Index (SCCAI) in ulcerative colitis. Key secondary endpoints include bio-naïve versus bio-experienced status, endoscopic healing, concurrent use of Epigallocatechin Gallate, albumin and inflammatory lab values, and smoking status. This study will look at the correlation between ustekinumab trough levels and these clinical outcomes in both Crohn's disease and ulcerative colitis. Results: Results pending. Conclusion(s): Conclusion to be determined.